Citius Oncology, Correlations

CTOR Stock

0.94 0.06 6.00%

The current 90-days correlation between Citius Oncology, and Procaps Group SA is 0.14 (i.e., Average diversification). The correlation of Citius Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Citius Oncology, Correlation With Market

Modest diversification

The correlation between Citius Oncology, and DJI is 0.25 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Citius Oncology, and DJI in the same portfolio, assuming nothing else is changed.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Oncology,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in Citius Stock, please use our How to Invest in Citius Oncology, guide.

Moving together with Citius Stock

0.82	VALN	Valneva SE ADR	Pair Corr
0.75	VRAX	Virax Biolabs Group	Pair Corr
0.86	ERNA	Eterna Therapeutics	Pair Corr
0.87	FDMT	4D Molecular Therapeutics	Pair Corr
0.8	ICU	LMF Acquisition Oppo	Pair Corr
0.78	IQV	IQVIA Holdings	Pair Corr
0.66	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.62	LLY	Eli Lilly Sell-off Trend	Pair Corr
0.77	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.68	GOVX	GeoVax Labs	Pair Corr
0.63	ICLR	ICON PLC	Pair Corr
0.65	ZVSA	ZyVersa Therapeutics	Pair Corr
0.71	IMMX	Immix Biopharma	Pair Corr
0.84	INKT	Mink Therapeutics	Pair Corr
0.65	SXTPW	60 Degrees Pharmaceu	Pair Corr
0.64	BIAFW	BioAffinity Technologies	Pair Corr

Moving against Citius Stock

0.8	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.72	ESPR	Esperion Therapeutics	Pair Corr
0.7	GILD	Gilead Sciences	Pair Corr
0.67	FLGC	Flora Growth Corp	Pair Corr
0.6	NBY	NovaBay Pharmaceuticals	Pair Corr
0.58	DRUG	Bright Minds Biosciences	Pair Corr
0.53	OPT	Opthea	Pair Corr
0.45	HCM	HUTCHMED DRC	Pair Corr
0.7	LPCN	Lipocine	Pair Corr
0.6	NAMS	NewAmsterdam Pharma	Pair Corr
0.56	ESLAW	Estrella Immunopharma	Pair Corr

Related Correlations Analysis

	PAHC	PROC	AMPH	ALKS	EOLS	PBH	PCRX	ITCI
PAHC		-0.51	0.18	0.29	-0.35	0.46	0.73	0.65	PAHC
PROC	-0.51		0.45	-0.23	0.86	-0.88	-0.39	-0.68	PROC
AMPH	0.18	0.45		-0.08	0.64	-0.37	0.25	0.0	AMPH
ALKS	0.29	-0.23	-0.08		-0.29	0.36	0.31	0.29	ALKS
EOLS	-0.35	0.86	0.64	-0.29		-0.88	-0.29	-0.6	EOLS
PBH	0.46	-0.88	-0.37	0.36	-0.88		0.41	0.78	PBH
PCRX	0.73	-0.39	0.25	0.31	-0.29	0.41		0.6	PCRX
ITCI	0.65	-0.68	0.0	0.29	-0.6	0.78	0.6		ITCI
	PAHC	PROC	AMPH	ALKS	EOLS	PBH	PCRX	ITCI

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

EOLS	+ 0.86	PROC
ITCI	+ 0.78	PBH
PCRX	+ 0.73	PAHC
ITCI	+ 0.65	PAHC
EOLS	+ 0.64	AMPH
ITCI	+ 0.6	PCRX

High negative correlations

PBH	- 0.88	EOLS
PBH	- 0.88	PROC
ITCI	- 0.68	PROC
ITCI	- 0.6	EOLS
PROC	- 0.51	PAHC
PCRX	- 0.39	PROC

Risk-Adjusted Indicators

There is a big difference between Citius Stock performing well and Citius Oncology, Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Citius Oncology,'s multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
PAHC	1.82	0.02	0.04	0.13	1.72	(2.08)	3.86	(2.45)	9.05
PROC	6.78	(0.16)	0.02	0.07	8.01	(11.46)	10.56	(13.11)	111.85
AMPH	1.60	(0.25)	0.00	(0.09)	0.00	0.00	3.37	(3.61)	17.30
ALKS	1.76	(0.16)	(0.03)	0.03	2.06	(1.94)	4.14	(3.59)	9.74
EOLS	2.44	(0.38)	0.00	(0.29)	0.00	0.00	4.49	(4.70)	22.78
PBH	0.94	0.12	0.07	0.29	1.04	(1.01)	1.90	(1.76)	4.90
PCRX	1.92	0.11	0.05	0.22	2.09	(2.11)	3.96	(3.67)	10.38
ITCI	1.35	0.14	0.07	0.30	1.33	(1.63)	3.04	(2.53)	16.17

Citius Oncology, Corporate Executives

Elected by the shareholders, the Citius Oncology,'s board of directors comprises two types of representatives: Citius Oncology, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Citius. The board's role is to monitor Citius Oncology,'s management team and ensure that shareholders' interests are well served. Citius Oncology,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Citius Oncology,'s outside directors are responsible for providing unbiased perspectives on the board's policies.

Jaime Bartushak

CFO Treasurer

Profile

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC